SFRP1 and osteoporosis: Combination of GapmeRs specifically designed for Sfrp1 silencing with one of the targeted delivery methods that are currently being developed would open the possibility of specifically silencing this gene in bone marrow MSCs and thus safely undertake the treatment of systemic bone loss such as that associated with osteoporosis.